News | Heart Valve Technology | October 18, 2022

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

Smaller Sheath Simplifies Access and Improves Ease-of-Use

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set.

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set. 

 


October 18, 2022 —  The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. As a result of its smaller size and other technological advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, reduce procedural steps and help improve outcomes. 

The Low Profile Sheath is the first sheath specifically engineered to be compatible with the Impella single-access technique, which removes the need for an additional access site. Additionally, it is designed to: 

Simplify access and ease-of-use by eliminating the peel-away sheath and the need for the re-access sheath for patients who are sent to the intensive care unit. 

Further minimize vascular complications and bleeding. 

Facilitate easier delivery into the vasculature with a hydrophilic coated long-taper dilator, reducing the need for multiple steps of serial dilation. 

Facilitate easier management of the patient during heart pump removal and vascular closure because Impella can be removed directly from the sheath without re-wiring. 

“Abiomed’s Low Profile Sheath is a game changing technological achievement that will further improve patient outcomes by making it even easier for physicians to insert, manage and remove Impella heart pumps,” said Chuck Simonton, MD, Abiomed’s chief medical officer. 

Abiomed will begin a phased roll-out of the Impella Low Profile Sheath this quarter. 

For more information: www.abiomed.com


Related Content

News | Heart Failure

September 25, 2023 — After world’s first successful transplant in 2022, also performed at the University of Maryland ...

Home September 25, 2023
Home
News | Heart Failure

September 15, 2023 — A team of interventional cardiologists from Henry Ford Health’s Center for Structural Heart Disease ...

Home September 15, 2023
Home
News | Heart Failure

September 13, 2023 — Socioeconomic status (education, income, employment status and health insurance) appears to be an ...

Home September 13, 2023
Home
News | Heart Failure

September 8, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home September 08, 2023
Home
News | Heart Failure

September 5, 2023 — Cedars-Sinai investigators are leaders in the innovation and use of transcatheter aortic valve ...

Home September 05, 2023
Home
News | Heart Failure

August 30, 2023 — “Joining forces to protect the heart – this was our mission for this year’s ESC Congress,” said ...

Home August 30, 2023
Home
News | Heart Failure

August 29, 2023 — The European Society of Cardiology (ESC) Guidelines on acute coronary syndromes are published online ...

Home August 29, 2023
Home
News | Heart Failure

August 28, 2023 — Ferric carboxymaltose(FCM) did not improve a hierarchical outcome of death, heart failure ...

Home August 28, 2023
Home
News | Heart Failure

July 28, 2023 — The Society of Thoracic Surgeons has launched its next-generation Operative Risk Calculator to assess ...

Home July 28, 2023
Home
News | Heart Failure

July 19, 2023 — The U.S. Food and Drug Administration (FDA) is recommending health care providers, laboratory personnel ...

Home July 19, 2023
Home
Subscribe Now